Search Results - "Merrouche, Y"

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France by Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.

“…The impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer…”
Get full text

Is oral chemotherapy prescription safe for patients? A cross-sectional survey by Bourmaud, A., Pacaut, C., Melis, A., Tinquaut, F., Magné, N., Merrouche, Y., Chauvin, F.

“…Oral chemotherapies are increasingly prescribed. Yet wide variations in prescription practices and in monitoring of toxicity have been underlined despite…”
Get full text

Relationship between nutritional status and quality of life in patients with cancer by Nourissat, A, Vasson, M.P, Merrouche, Y, Bouteloup, C, Goutte, M, Mille, D, Jacquin, J.P, Collard, O, Michaud, P, Chauvin, F

“…Abstract Patients with cancer frequently suffer a deteriorated quality of life and this is an important factor in the therapeutic decision. The correlation…”
Get full text

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes by De Masson, A., Giustiniani, J., Marie-Cardine, A., Bouaziz, J. D., Dulphy, N., Gossot, D., Validire, P., Tazi, A., Garbar, C., Bagot, M., Merrouche, Y., Bensussan, A.

“…CD245 is a human surface antigen expressed on peripheral blood lymphocytes, initially delineated by two monoclonal antibodies DY12 and DY35. Until now, CD245…”
Get full text

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors by Marty, M., Fumoleau, P., Adenis, A., Rousseau, Y., Merrouche, Y., Robinet, G., Senac, J., Puozzo, C.

“…Summary Background Vinorelbine is a vinca alkaloid obtained by hemi-synthesis, which makes the molecule more lipophilic than the other vincas An injectable…”
Get full text

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy by Rougier, P, Bugat, R, Douillard, J Y, Culine, S, Suc, E, Brunet, P, Becouarn, Y, Ychou, M, Marty, M, Extra, J M, Bonneterre, J, Adenis, A, Seitz, J F, Ganem, G, Namer, M, Conroy, T, Negrier, S, Merrouche, Y, Burki, F, Mousseau, M, Herait, P, Mahjoubi, M

“…To assess the efficacy of irinotecan (CPT-11) in the treatment of advanced colorectal cancer in both chemotherapy-naive and pretreated patients. Two hundred…”
Get more information

Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer by Merrouche, Y., Mugneret, F., Cahn, J.-Y.

Get full text

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) by Bugat, R, Bataillard, A, Lesimple, T, Voigt, J J, Culine, S, Lortholary, A, Merrouche, Y, Ganem, G, Kaminsky, M C, Negrier, S, Perol, M, Laforêt, C, Bedossa, P, Bertrand, G, Coindre, J M, Fizazi, K

Get full text

Carcinoma of an unknown primary: are EGF receptor, Her-2 neu, and c-Kit tyrosine kinases potential targets for therapy? by MASSARD, C, VOIGT, J.-J, PIVOT, X, COUDERT, B, DOUILLARD, J.-Y, MERROUCHE, Y, FIZAZI, K, LAPLANCHE, A, CULINE, S, LORTHOLARY, A, BUGAT, R, THEODORE, C, PRIOU, F, KAMINSKY, M.-C, LESIMPLE, T

“…Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new…”
Get full text

ESTIMATED COSTS OF HER2-POSITIVE METASTATIC BREAST CANCER FOR PATIENTS INITIATING AN ORAL ANTICANCER TREATMENT: RESULTS FROM A FRENCH PROSPECTIVE OBSERVATIONAL STUDY by Woronoff-Lemsi, M.C, Chaix-Couturier, C, Durand-Zaleski, I, Espié, M, Lortholary, A, Merrouche, Y, Flinois, A, Chabernaud, H, Benjamin, L

Get full text

5069 POSTER Phase II Study Assessing Lapatinib Added to Letrozole in Patients With Progressive Disease Under Aromatase Inhibitor in Metastatic Breast Cancer – Study BES 06 by Villanueva, C, Chaigneau, L, Romieu, G, Salvat, J, N'Guyen, T, Merrouche, Y, Dramard, M.H, Goetscheld, A, Bazan, F, Pivot, X

Get full text

Estimation of the risk for nutritional state degradation in patients with cancer: development of a screening tool based on results from a cross-sectional survey by Nourissat, A., Mille, D., Delaroche, G., Jacquin, J. P., Vergnon, J. M., Fournel, P., Seffert, P., Porcheron, J., Michaud, P., Merrouche, Y., Chauvin, F.

“…Background: In routine practice, the evaluation of the nutritional status of patients with cancer is not always performed although there is frequent…”
Get full text

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06 by Villanueva, C., Romieu, G., Salvat, J., Chaigneau, L., Merrouche, Y., N’Guyen, T., Vuillemin, A. Thiery, Demarchi, M., Dobi, E., Pivot, Xavier

“…This trial evaluated the effect of adding lapatinib to letrozole after clinical resistance to aromatase inhibitor (IA) treatment in hormone receptor-positive…”
Get full text

Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients by Smith, D, Bosacki, C, Merrouche, Y

“…Cetuximab and panitumumab are anti-EGF receptor antibodies, used in the treatment of colorectal cancer. Phase I and II studies have shown an interest in these…”
Get more information

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer by YCHOU, M, RAOUL, J. L, COUTEAU, C, MERROUCHE, Y, DESSEIGNE, F, BOREL, C, CAROLI-BOSC, F. X, JACOB, J. H, SEITZ, J. F, KRAMAR, A, HUA, A, LEFEBVRE, P

“…The efficacy and safety of single-agent, high-dose irinotecan (CPT-11, Campto) 500 mg/m(2) every 3 weeks were investigated as first-line treatment for advanced…”
Get full text

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers by Escudier, B, Droz, J P, Rolland, F, Terrier-Lacombe, M J, Gravis, G, Beuzeboc, P, Chauvet, B, Chevreau, C, Eymard, J C, Lesimple, T, Merrouche, Y, Oudard, S, Priou, F, Guillemare, C, Gourgou, S, Culine, S

“…We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell…”
Get more information

Carcinoma of an unknown primary: are EGF receptor, Her-2 neu, and c-Kit tyrosine kinases potential targets for therapy? by Massard, C, Voigt, J-j, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-c, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-y, Merrouche, Y, Fizazi, K

Get full text

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study by Merrouche, Y, Extra, J M, Abigerges, D, Bugat, R, Catimel, G, Suc, E, Marty, M, Hérait, P, Mahjoubi, M, Armand, J P

“…To assess, on a multicenter basis, the feasibility of treating advanced cancer patients with high-dose irinotecan. Thirty-five patients who met the usual phase…”
Get more information

Small-cell carcinoma of the esophagus: Report of three cases and review of the literature with emphasis on therapy by Madroszyk, A., Egreteau, J., Martin, L., Queneau, P. E., Bosset, J. F., Merrouche, Y.

“…Summary Primary small-cell carcinoma (SCC) of the esophagus is rare, with about 200 cases reported up till now in the literature Like pulmonary SCC, it is an…”
Get full text

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer by Chevallier, B, Chollet, P, Merrouche, Y, Roche, H, Fumoleau, P, Kerbrat, P, Genot, J Y, Fargeot, P, Olivier, J P, Fizames, C

“…To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral…”
Get more information